In general, the ultracentrifugally defined low density lipoproteins, and the electrophoretically or chemically separated A-lipoproteins, demonstrate a close correlation with clinical coronary atherosclerotic disease, whereas the smaller high density (alpha*) lipoproteins do not. Since all lipoproteins contain cholesterol in varying concentrations, it is apparent that cholesterol levels on the one hand and low density or beta lipoprotein levels on the other are not necessarily parallel.
A body of evidence has been accumulating which suggests that heparin plays a physiologic role in the serum transport phase of fat metabolism. Chargaff The patients were all told they would receive injections of a new medication which seemed promising in the therapy of atherosclerosis. One group was given 200 mg. of concentrated aqueous heparint (100 mg. or 200 mg. per cc.) subcutaneously twice weekly, and the other received isotonic saline placebo injections in a similar manner. In all other respects, therapy was identical in the two groups. Vasodilating drugs were prescribed when needed for angina or claudication and hypertension was treated by the usual methods. Diabetic therapy was supervised in the diabetic clinic. Low fat diets were not prescribed except when caloric restriction was indicated for obesity, attempts at weight reduction in these clinic patients were usually unsuccessful. Oral anticoagulant drugs were not used. A fair percentage of the patients in both groups, or their close relatives, were taught to give the injections at home, usually at bedtime.t Where this was not feasible, the patients in both groups came to the clinic for the medication. It was injected slowly in the relatively painless subcutaneous tissue just above or below the posterior iliac crest, using a 25 gage hypodermic needle. One technician gave all the injections in the clinic and was the only person, apart from the authors, who knew whether the patient was receiving heparin or the placebo. This project was not conducted as a blind study, since symptomatic results were not being evaluated and it seemed safer, in view of the anticoagulant action of heparin, for us to know what each patient received.
Several considerations led to the selection of the 200 mg. dose of subcutaneous aqueous heparin twice weekly, although we appreciated the fact that this might not be sufficient for a marked sustained lipoprotein reduction particularly in patients with highly elevated levels. It had previously been found' that 200 mg. of repository heparin produced a substantial though temporary drop in the low density lipoproteins. The subcutaneous route was more practical than the intravenous one; it avoided the extremely high peaks of anticoagulant activity and afforded a much more sustained reduction of lipoproteins. Furthermore, subcutaneously administered concentrated aqueous heparin, which has anticoagulant and lipoprotein effects similar to intramuscular repository heparin, is far less painful, less expensive and much easier to administer than the latter. Although injections of 200 mg. of heparin three times weekly would have afforded a greater average lowtering of lipoproteins, we were limited by the amount of heparin available to us, and by the consideration that we wanted to minimize the duration of the anticoagulant effect. It had previously been found23 24 that therapeutic levels of anticoagulant activity are maintained for an average of 16 to 18 hours after a 200 mg. subcutaneous dose of concentrated aqueous heparin.
The following criteria were adopted at the onset of the study as affording objective evidence of progress of the underlying atherosclerotic process: (1) cardiovascular death; (2) recurrence of myocardial infarction; (3) gangrene of a limb necessitating amputation and (4) a cerebral vascular accident with objective findings of resultant cerebral damage. When patients were hospitalized, the diagnosis of the in-patient attending staff (who did not know whether heparin or the placebo had been given) was accepted as to whether an infarction had occurred or not. Since we could not logically anticipate any effect of heparin therapy on the atherosclerotic process in a few weeks, recurrences during the first month after the onset of treatment in either group were not included in the results. Table 1 shows the composition of the two groups. The control series is slightly larger since our heparin supply was adequate for only slightly more than 100 patients. The groups were fairly well balanced, although the patients were alternately allocated with no attempt at matching, in order to eliminate bias in the selection. The heparin series was slightly older and heavier and had somewhat more elevated lipid values, whereas there were proportionately more hypertensives and diabetics in the placebo group and a slightly higher average number of previous infarctions per patient. Chi square analysis These changes are typical of the effect of heparin. of each of these possibly important factors, however, reveals that these variations were statistically insignificant. It is evident that these were older individuals with elevated serum lipoproteins, a factor perhaps related to the fairly high proportion of diabetics in the study. Although it would have been desirable to classify the severity of the previous infarction, we were unable to do so as adequate information was not available in many of the patients. However, we believe the extent and severity of the prior episodes of myocardial infarction were comparable in both series. Table 2 summarizes the results of the twoyear study. In the placebo group there were 18 nonfatal recurrences (14 myocardial infarctions, 3 cerebral episodes, and 1 leg amputation for gangrene) and 21 cardiovascular deaths (2 following known cerebral accidents, 2 in congestive failure and 17 after an acute infarction or just sudden death). Thus the death rate in the control patients was approximately 10 per cent per year, which is in keeping with the anticipated yearly mortality in any large group of elderly patients with coronary heart disease. In this group, the recurrences and deaths occurred fairly regularly throughout the period of the study.
RESULTS
In the heparin group, there were 5 nonfatal recurrences (three acute myocardial infarctions and two minor cerebral episodes) and four cardiovascular deaths. The recurrences occurred after 7, 10, 13, 18 and 19 months of therapy and the fatalities after 2, 4, 19 and 21 months. Postmortem examination in 3 of these 4 patients revealed old and recent myocardial infarction in two, and an old but no recent infarct in the third case. No autopsy was obtained in the fourth patient who collapsed and died while at work. There were no known cerebral deaths, and no fatalities due to severe congestive failure without recent acute infarction in the patients who received heparin. The death rate in this group was 2 to 2.5 per cent per year.
In our opinion the number of cardiovascular deaths is the most reliable index for evaluation since the diagnosis is beyond question. Statistically, using the figures for deaths and total patient months of therapy, the observed differences in proportions of deaths between the two series is 3.3 times the standard error of the difference in proportions or p < .01. If the x square test is applied, using total deaths and number of patients (and disregarding the fact that the patients receiving heparin had slightly more months of therapy per patient), p is between 0.01 and 0.001. Thus, using either calculation, the difference in deaths is statistically significant.
Since to our knowledge, this is the first instance in which fairly large doses of heparin have been given intermittently for several years in a sizeable number of patients, the symptomatic response was carefully recorded. Although for reasons of safety, blind study technics were not employed, the patients' observations were of interest to us.
As is usually noted, 25 to 35 per cent of the control group reported decreased symptoms on placebo therapy, but the favorable response gradually decreased in some patients. Symptomatic improvement occurred in 50 to 75 per cent of the patients who received heparin and was usually fairly well maintained. We also noted that most often, in contrast to the placebo patients, there was slowly progressive improvement for several months in the heparin group. The patients reported improvement in headaches, vertigo, tinnitus, angina, dyspnea, hip and thigh pain, claudication, weak spells and fatigue, all of which may be symptoms of widespread atherosclerosis. A generally improved sense of well being with an increased effort tolerance was the usual response after several months of heparin therapy. Table 3 shows the complications that were encountered in the heparin group, other than minor ecchymoses at the site of injection which occurred occasionally in most of the patients and were insignificant. There were three instances of major hemorrhage; two were intestinal and one was renal. X-ray study revealed adenocarcinoma of the stomach in one patient and a kidney stone in another. Thus, there was only one instance of major hemorrhage that was apparently due to the heparin itself and in this patient the drug was not continued. There were no hemorrhagic fatalities. There were six minor episodes of bleeding: one nasal, four rectal and one pulmonary. All the rectal cases had had previous hemorrhoidal bleeding and the patient with bloody sputum had known bronchiectasis. Heparin was successfully continued in all, except in the patient with bronchiectasis where further therapy was not given as bleeding occurred after each injection. There were two instances of post-traumatic minor hemorrhage: one followed a tongue bite incurred while chewing, and the other occurred when a small rectal abscess was mistakenly incised one hour after an injection of heparin. During the entire study intravenous protamine sulfate* was used three times for bleeding and was very efficacious. There were only three instances of large, painful hematomata at the site of injection. The use of small needles and a slow speed of injection were important factors in minimizing the occurrence of local ecchymoses. Six patients complained of an increase in discrete ecchymotic spots remote from the injection site. All were given oral P factor therapyt for several months which was helpful. Thrombophlebitis of the leg veins occurred in two patients while on heparin therapy, perhaps related to a rebound effect. One of these patients had a nonfatal pulmonary infarct and refused to continue the heparin. He was then dropped from the study and was subsequently uneventfully maintained on oral anticoagulants. In the other patient heparin was subsequently successfully continued in 150 mg. doses three times weekly in order to decrease the interval between injections and so possibly decrease any rebound effect. Three patients had lumbar pain and three had urticaria following each dose of heparin. All six had relief from these complaints, when colorless heparin was used instead of light brown material, indicating that these symptoms were not due to heparin itself. One patient had a severe asthmatic reaction after every heparin injection regardless of the color of the material and was forced to discontinue therapy despite the concomitant use of antihistamine drugs. In four patients a mildmoderate alopecia occurred.
In all, heparin therapy was stopped in four cases because of complications. It 24 hours, in others the effect is more prolonged. Unfortunately, we only have lipoprotein determinations in a small percentage of the patients after 6 to 18 months of heparin therapy. In most of these the serum lipoprotein levels 48 hours after the previous dose of heparin were approximately the same as prior to the onset of therapy. In a few however, the low density lipoproteins, determined 48 to 72 hours after the last dose of heparin so as to avoid its acute effects, were considerably below control levels (table 5 ). It appears that in a minority of the patients, there is a marked sustained reduction in the average level of low density lipoproteins (on the dosage schedule administered), whereas the majority have only a temporary (24 to 36 hour) decrease following each injection of heparin. Cholesterol levels are variable in the 24 hours after 200 mg. of heparin is given subcutaneously and show relatively little change (perhaps a slight reduction in some instances), when determined after 6 to 18 months of therapy.
DIscussIoN
In view of the multiplicity of actions of heparin and the numerous factors which may play a role in the progress of atherosclerotic disease, it is difficult to assess accurately the differential role of the various mechanisms through which heparin produced the beneficial effects noted in this study. As found a reduction in mortality over a three year period from 10 per cent per year in his control group to 4.7 per cent per year in his patients on a rigid (25 Gm.) low fat diet, a ratio of slightly better than 2:1. However, most patients will not strictly adhere to a low fat diet, and in our experience the diet alone does not effectively reduce serum lipids and lipoproteins in all instances. The prolonged use of oral anticoagulants has also been reported [26] [27] [28] to reduce the incidence of recurrences and death in approximately a 2: 1 or 3: 1 ratio. However, the incidence of major hemorrhage in these series was not small, even with good laboratory controls. Moreover, since the prothrombin depressing drugs do not have any effect upon serum lipoproteins, it is probable that although they reduce the occurrences of thrombotic incidents, they retard the basic atheromatous process very little if at all. 26 Estrogens have recently been advocated since they reduce the concentration of the ,8-lipoproteins. However, the large doses required produce such severe feminizing side effects that this form of therapy is most distressing, psychologically traumatic and impractical, 41 (5) Le supra-describite maniera de administrar heparina non resulta in un mantenentia de therapeutic nivellos anticoagulante. Tests del tempore de coagulation es consequentemente innecessari.
